Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

09/18/2021 | 09:12am EDT
Ground-breaking Phase III head-to-head DESTINY-Breast03 results featured at ESMO Presidential Symposium support Enhertu as the potential new standard of care in previously treated patients

DESTINY-Breast01 Phase II trial data also presented at ESMO showed impressive median overall survival of 29.1 months in HER2-positive patients following two or more HER2-based regimens

Disclaimer

AstraZeneca plc published this content on 18 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 September 2021 13:11:04 UTC.


© Publicnow 2021
All news about ASTRAZENECA PLC
10:00aASTRAZENECA : Credit Suisse remains its Buy rating
MD
09:07aASTRAZENECA : Announces Winners and Recognizes Oncology Change Makers in Third Annual Canc..
BU
08:51aASTRAZENECA : Air Malta Transports Maltese Solidarity to Rwanda; 135,690 AstraZeneca vacci..
AQ
04:44aKAROLINSKA INSTITUTET : Two COVID-19 Vaccine Doses Increase Airway Antibodies After Infect..
MT
03:02aMODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
03:01aASTRAZENECA : Conference Chair Di Morris, AstraZeneca Invites You to Join SMi's 10th Annua..
AQ
01:55aLONDON STOCK EXCHANGE : Nearly half of FTSE 100 companies have no net-zero target, Arabesq..
RE
01:10aASTRAZENECA : India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say
RE
10/19ASTRAZENECA : WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document
RE
10/19MODERNA : Germany may miss COVID-19 vaccine donation goal, blames manufacturers
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 422 M - -
Net income 2021 4 868 M - -
Net Debt 2021 24 833 M - -
P/E ratio 2021 25,3x
Yield 2021 3,21%
Capitalization 136 B 188 B -
EV / Sales 2021 4,54x
EV / Sales 2022 3,65x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 87,68 $
Average target price 137,86 $
Spread / Average Target 57,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC19.32%186 853
JOHNSON & JOHNSON4.12%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.12.25%235 986
ELI LILLY AND COMPANY43.51%219 674